# Mesa Laboratories Inc: Form 10-Q for the period ended Sep 30, 2019

- Company: [Mesa Laboratories Inc](/companies/mlab.md) (CIK 724004)
- Form: 10-Q
- Filed: 2019-11-06
- Accepted by EDGAR: Nov 6, 2019, 08:11 ET
- Period: 2019-09-30
- Accession: 0001437749-19-021657
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/724004/000143774919021657/mlab20190930_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/724004/000143774919021657/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $25.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2019-04-01 to 2019-09-30 | $51.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $10.1m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2019-04-01 to 2019-09-30 | $20.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $15.5m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2019-04-01 to 2019-09-30 | $31.6m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-07-01 to 2019-09-30 | $915.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2019-04-01 to 2019-09-30 | $1.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | $4.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2019-04-01 to 2019-09-30 | $10.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $602.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2019-04-01 to 2019-09-30 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | $3.1m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months, 2019-04-01 to 2019-09-30 | $7.7m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.71 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2019-04-01 to 2019-09-30 | $1.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.74 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2019-04-01 to 2019-09-30 | $1.90 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-30 | 4,321,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2019-04-01 to 2019-09-30 | 4,205,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2019-04-01 to 2019-09-30 | $7.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2019-04-01 to 2019-09-30 | $543.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2019-04-01 to 2019-09-30 | $1.3m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2019-09-30 | $245.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $270.7m | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $392.5m | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $16.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $163.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-09-30 | $229.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 27,692 characters.

### Forward Looking Statements

*This report contains information that may constitute "forward-looking statements.” Generally, the words "believe," "will," "expect," "anticipate," "intend," "project," "estimate," and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events, or developments that we expect or anticipate will occur in the future — including statements relating to revenues growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to those described in Part II, "Item 1A. Risk Factors" and elsewhere in this report and in our Annual Report on Form 10-K for the year ended March 31, 2019, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.*

### General Discussion

We pursue a strategy of focusing primarily on quality control products and services, which are sold into niche markets that are driven by regulatory requirements. We prefer markets in which we can establish a strong presence and achieve high gross margins. As of September 30, 2019, we are organized into four divisions, or segments. Our Sterilization and Disinfection Control Division manufactures and sells biological, cleaning, and chemical indicators. Biological, cleaning, and chemical indicators are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. Our Instruments Division designs, manufactures, and markets quality control instruments and disposable products utilized in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. Our Cold Chain Monitoring Division designs, develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. Our Cold Chain Packaging Division ("the Packaging Division"), which we plan to exit no later than March 31, 2020, provides thermal packaging products such as coolers, boxes, insulation materials, and phase-change products to control temperature during the customer’s transport of their own products.

Our revenues come from product sales, which include hardware, software, and consumables; as well as services, which include installation, discrete maintenance services, and ongoing maintenance contracts. Product sales (hardware, software, and consumables) are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products, and acquisitions. Sterilization and disinfection control products and most products in our Packaging Division are disposable and are used on a routine basis, thus product sales are less sensitive to general economic conditions. Instrument products and cold chain monitoring products and systems have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Cold chain monitoring and instruments products may be sold in conjunction with a perpetual or subscription-based software license, which may be required for the related hardware to function. Service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our instrument products and cold chain monitoring systems. We typically evaluate costs and pricing annually. Our policy is to price our products competitively and, where possible, we pass along cost increases in order to maintain our margins.

Gross profit is affected by our product mix, manufacturing efficiencies, and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross margin percentages for some products have improved. There are, however, differences in gross margin percentages between product lines, and ultimately the mix of sales will continue to impact our overall gross margin.

In April 2019 we completed a business combination (the “IBP Acquisition”) whereby we acquired the common stock of IBP Medical GmbH ("IBP"), a company whose business manufactures medical meters used to test various parameters of dialysis fluid (dialysate), and the proper calibration and operation of a dialysis machine.

On October 31, 2019, we completed a business combination (the "GPT Acquisition") whereby we acquired the common stock of Gyros Protein Technologies Holding AB ("GPT"), a company whose business provides Immunoassay and Peptide Synthesis solutions that accelerate the discovery, development and manufacturing of biotherapeutics. The acquisition price for Gyros consisted of cash consideration of $180,000, subject to purchase price adjustments. The acquisition deepens our commitment to biopharmaceutical quality control and is the core of our new division, or segment, Biopharmaceutical Development.

As a result of the GPT Acquisition, we will incur a significant amount of additional stock compensation expense during the three months ending December 31, 2019 and thereafter, related to the impact of the GPT Acquisition on our ability to achieve vesting targets on certain outstanding performance-based restricted stock units.

### General Trends

Our strategic financial objectives include growth both organically and through further acquisitions. During the six months ended September 30, 2019, we worked to maximize the efficiency of our operations to prepare for future growth, including hiring key personnel to our operations and sales and marketing teams, and leveraging *The Mesa Way*, our customer-centric, lean-based system for continuously improving and operating a set of high-margin, niche businesses.

The markets for sterilization and disinfection control products remain strong, as the disposable nature of these products makes them less sensitive to general economic conditions. The worldwide market for sterilization and disinfection control products is growing as more countries focus on verifying the effectiveness of sterilization and disinfection processes.

Demand for our instruments products and cold chain services and monitoring systems remains solid and we strive to continue to grow revenues going forward. In general, our instruments products and cold chain monitoring systems are more impacted by general economic conditions than our sterilization and disinfection control and cold chain packaging products. As a result, uncertainty about global economic conditions may cause businesses to postpone spending in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values. Worldwide and regional economic conditions could also reduce the demand for our products and services, as our customers reduce or delay capital equipment and other types of purchases.

We are working on several research and development projects that, if completed, may result in enhanced or new products for both existing customers and new markets. We are hopeful that we will have enhanced or new products and services available for sale in the coming year.

As discussed in Note 6. Indebtedness within Item 1. "Financial Statements," we completed a convertible debt offering and an equity offering on our common stock, which provided $252,065, net of discounts and debt issuance costs. We intend to use the money raised to continue our acquisition strategy and for general corporate purposes.

Overall revenues increased 4% for the six months ended September 30, 2019. Organic revenues growth by reporting segment was as follows:

|  | Three Months Ended September 30, 2019 | Six Months Ended September 30, 2019 |
| --- | ---: | ---: |
| Sterilization and Disinfection Control | 4% | 6% |
| Instruments | (3%) | 1% |
| Cold Chain Monitoring | 16% | 1% |
| Cold Chain Packaging | (45%) | (36%) |
| Total Company | -- | -- |
| **Total Company excluding Cold Chain Packaging** | **3%** | **3%** |

As previously announced, during the year ended March 31, 2019, we made the decision to exit the packaging business by or before March 31, 2020. We have stopped providing consulting services, and we are no longer seeking or accepting new customers. We have reduced the division's costs by relocating most of the administrative functions to our headquarters in Lakewood, Colorado, and eliminating the division's sales force. Throughout the six months ended September 30, 2019, we assisted our customers in transitioning their business to other packaging vendors. During the three months ending December 31, 2019 we have stopped purchasing new inventory and providing complete packaging solutions. We are continuing the process of liquidating our remaining inventory and exiting the business.

### Results of Operations

(Dollars in thousands)

The following table sets forth, for the periods indicated, Condensed Consolidated Statements of Income data. The table and the discussion below should be read in conjunction with the accompanying Condensed Consolidated Financial Statements and the notes thereto appearing elsewhere in this report:

|  | Three Months Ended September 30, 2019 | 2018 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $25,536 | $24,865 | $671 | 3% |
| Cost of revenues | 10,060 | 10,288 | (228) | (2%) |
| Gross profit | $15,476 | $14,577 | $899 | 6% |
| Gross profit margin | 61% | 59% | 2% |  |
| Operating expenses |  |  |  |  |
| Selling | $2,274 | $1,804 | $470 | 26% |
| General and administrative | 7,703 | 7,493 | 210 | 3% |
| Research and development | 915 | 842 | 73 | 9% |
| Legal settlement | -- | 3,300 | (3,300) | (100%) |
| Total operating expenses | $10,892 | $13,439 | $(2,547) | (19%) |
| Operating income | $4,584 | $1,138 | $3,446 | 303% |
| Net income | 3,062 | 994 | 2,068 | 208% |
| Net income margin | 12% | 4% | 8% |  |

Page 15

|  | Six Months Ended September 30, 2019 | 2018 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $51,824 | $50,007 | $1,817 | 4% |
| Cost of revenues | 20,209 | 20,339 | (130) | (1%) |
| Gross profit | $31,615 | $29,668 | $1,947 | 7% |
| Gross profit margin | 61% | 59% | 2% |  |
| Operating expenses |  |  |  |  |
| Selling | $4,482 | $3,694 | $788 | 21% |
| General and administrative | 15,223 | 15,093 | 130 | 1% |
| Research and development | 1,934 | 1,679 | 255 | 15% |
| Legal settlement | -- | 3,300 | (3,300) | (100%) |
| Total operating expenses | $21,639 | $23,766 | $(2,127) | (9%) |
| Operating income | $9,976 | $5,902 | $4,074 | 69% |
| Net income | 7,659 | 5,224 | 2,435 | 47% |
| Net income margin | 15% | 10% | 5% |  |

### Revenues

The following tables summarize our revenues by source:

|  | Three Months Ended September 30, 2019 | 2018 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Sterilization and Disinfection Control | $12,094 | $11,582 | $512 | 4% |
| Instruments | 8,960 | 8,704 | 256 | 3% |
| Cold Chain Monitoring | 3,586 | 2,950 | 636 | 22% |
| Cold Chain Packaging | 896 | 1,629 | (733) | (45%) |
| Total | $25,536 | $24,865 | $671 | 3% |

|  | Six Months Ended September 30, 2019 | 2018 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Sterilization and Disinfection Control | $24,204 | $22,930 | $1,274 | 6% |
| Instruments | 18,504 | 17,435 | 1,069 | 6% |
| Cold Chain Monitoring | 6,903 | 6,173 | 730 | 12% |
| Cold Chain Packaging | 2,213 | 3,469 | (1,256) | (36%) |
| Total | $51,824 | $50,007 | $1,817 | 4% |

#### Three and Six Months Ended September 30, 2019 versus September 30, 2018

Sterilization and Disinfection Control revenues increased 4% and 6% for the three and six months ended September 30, 2019, respectively, as a result of organic revenues growth, which was achieved primarily through volume increases with existing customers and modest price increases.

Instruments revenues increased 3% and 6% for the three and six months ended September 30, 2019, respectively, primarily due to the acquisition of IBP in April 2019.

Cold Chain Monitoring revenues increased 22% and 12% for the three and six months ended September 30, 2019, respectively, as a result of the acquisition of Point Six Wireless, LLC ("Point Six") in the prior year and organic revenues growth which was achieved primarily through volume increases with existing and new customers. Revenues in this division have historically fluctuated quarter over quarter due to the timing of performance obligations and the nature and timing of orders and installations within any given quarter.

Cold Chain Packaging revenues decreased 45% and 36% for the three and six months ended September 30, 2019, respectively, as a result of our decision to exit the business and cease accepting new customers, completing our sales contract with our largest customer, and our assisting of our current customers in transitioning their business to other vendors.

### Gross Profit

The following summarizes our gross profit by segment:

|  | Three Months Ended September 30, 2019 | 2018 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Sterilization and Disinfection Control | $8,720 | $7,972 | $748 | 9% |
| Gross profit margin | 72% | 69% | 3% |  |
| Instruments | 5,545 | 5,354 | 191 | 4% |
| Gross profit margin | 62% | 62% | --% |  |
| Cold Chain Monitoring | 1,126 | 1,164 | (38) | (3%) |
| Gross profit margin | 31% | 39% | (8%) |  |
| Cold Chain Packaging | 85 | 87 | (2) | (2%) |
| Gross profit margin | 9% | 5% | 4% |  |
| Total gross profit | $15,476 | $14,577 | $899 | 6% |
| Gross profit margin | 61% | 59% | 2% |  |

|  | Six Months Ended September 30, 2019 | 2018 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Sterilization and Disinfection Control | $17,225 | $15,784 | $1,441 | 9% |
| Gross profit margin | 71% | 69% | 2% |  |
| Instruments | 11,608 | 10,987 | 621 | 6% |
| Gross profit margin | 63% | 63% | --% |  |
| Cold Chain Monitoring | 2,370 | 2,628 | (258) | (10%) |
| Gross profit margin | 34% | 43% | (9%) |  |
| Cold Chain Packaging | 412 | 269 | 143 | 53% |
| Gross profit margin | 19% | 8% | 11% |  |
| Total gross profit | $31,615 | $29,668 | $1,947 | 7% |
| Gross profit margin | 61% | 59% | 2% |  |

#### Three and Six Months Ended September 30, 2019 versus September 30, 2018

Sterilization and Disinfection Control gross profit margin percentage increased 3 and 2 percentage points for the three and six months ended September 30, 2019, respectively, primarily as a result of efficiencies gained both operationally and from higher sales volumes.

Instruments gross profit margin percentage was flat during both the three months ended September 30, 2019, primarily due to efficiencies gained both operationally and from higher sales volumes, offset by product and service mix.

Cold Chain Monitoring gross profit margin percentage decreased 8 and 9 percentage points for the three and six months ended September 30, 2019, respectively, primarily due to lower than planned service revenues volumes, higher than expected hardware prices from certain vendors and timing associated with the completion of certain projects. As we finalize a more cohesive road-map for consolidation of our various product offerings, we expect gross margin percentages to gradually improve to 40%-45%.

Cold Chain Packaging gross profit margin percentage increased 4 and 11 percentage points for the three and six months ended September 30, 2019, respectively, primarily as a result of implementing price increases as part of our plan to exit the business by March 31, 2020. Also contributing to the increase were lower operating and personnel expenses and the completion of our sales contract with the division's largest customer which historically was one of our lower margin customers as a percentage of revenues.

### Operating Expenses

Operating expenses for the three and six months ended September 30, 2019 decreased 19% and 9%, respectively as compared to the prior year as follows:

### Selling

#### Three and Six Months Ended September 30, 2019 versus September 30, 2018

Selling expense is driven primarily by labor costs, including salaries and commissions; accordingly, it may vary with sales levels. Selling expense for the three and six months ended September 30, 2019 increased 26% and 21%, respectively, as we back-filled open sales and marketing positions and incurred higher professional services costs associated with investments in our technological infrastructure in an effort to modernize our marketing program. As a percentage of revenues, selling expense was 9% for both the three and six months ended September 30, 2019 as compared to 7% for both the three and six months ended September 30, 2018. We plan to continue making modest, strategic investments in sales and marketing resources in order to further increase organic revenues growth.

### General and Administrative

#### Three and Six Months Ended September 30, 2019 versus September 30, 2018

Labor costs, including non-cash stock-based compensation and amortization of intangible assets drive the substantial majority of general and administrative expense. General and administrative expenses for the three and six months ended September 30, 2019 increased 3% and 1%, respectively, primarily due to increased equity-based compensation expense, partially offset by decreased amortization of intangible assets as we wind down our Packaging Division.

### Research and Development

#### Three and Six Months Ended September 30, 2019 versus September 30, 2018

Research and development expense is predominantly comprised of labor costs and costs of third-party consultants. Research and development expenses for the three and six months ended September 30, 2019 increased 9% and 15%, respectively, due to increases in salary expense as we staff our engineering department to support our continued incremental investments in enhancing existing products as well as the development of new products and features.

### Legal Settlement

#### Three and Six Months Ended September 30, 2019 versus September 30, 2018

During the three months ended September 30, 2018 we recorded a $3,300 estimated legal settlement expense; see Note 10. "Commitments and Contingencies" within Item 1. *Financial Statements.*

### Other Expense

Other expense for the three and six months ended September 30, 2019 is composed primarily of interest expense associated with our Credit Facility and convertible senior notes (the "Notes"), gains and losses on sales of property, plant and equipment, and gains and losses on foreign currency transactions. Interest expense, net for the three and six months ended September 30, 2019 increased by $684 and $474, respectively, compared to the three and six months ended September 30, 2018 primarily due to interest expense related to the Notes issued in August 2019, partially offset by interest earned on our investments in money market securities.

### Net Income

Our income tax rate varies based upon many factors but in general, we anticipate that on a go-forward basis, our effective tax rate will be approximately 26%, plus or minus the impact of excess tax benefits and deficiencies associated with share-based payment awards to employees; see Note 9. “Income Taxes” within Item 1. *Financial Statements* for additional discussion. The excess tax benefits and deficiencies associated with share-based payment awards to our employees have caused and, in the future, may cause large fluctuations in our realized effective tax rate based on timing, volume, and nature of stock options exercised under our share-based payment program. Net income for the six months ended September 30, 2019 varied with the changes in revenues, gross profit, and operating expenses (which includes $3,330, $2,050 and $597 of non-cash amortization of intangible assets, stock-based compensation, and interest expense respectively).

### Liquidity and Capital Resources

Our sources of liquidity include cash generated from operations, cash equivalents, working capital and potential additional equity and debt offerings. We believe that cash and cash equivalents on hand and cash generated from these sources will be sufficient to meet our short-term and long-term needs. Our more significant uses of resources have historically included acquisitions, long-term capital expenditures, payment of debt and interest obligations, and quarterly dividends to shareholders. Working capital is the amount by which current assets exceed current liabilities. We had working capital of $253,987 and $9,962 at September 30, 2019, and March 31, 2019, respectively. As of September 30, 2019, we had $245,443 of cash and cash equivalents, which were held primarily in money market funds. We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

We paid off the interest bearing debt issued under our Term Loan and Line of Credit during the three months ended September 30, 2019 and terminated the Credit Facility in October 2019 due to the issuance of the Notes.

In addition, as of September 30, 2019, we held $172,500 in aggregate principal amount of convertible senior notes. The Notes bear interest at a rate of 1.375% payable semi-annually in arrears on February 15 and August 15 of each year, beginning with a payment on February 15, 2020. These Notes can be converted prior to maturity if certain conditions are met. We currently expect to settle future conversions of the Notes entirely in shares of our common stock and will reevaluate this policy from time to time as conversion notices are received from holders of the Notes. We were in compliance with all loan agreements at September 30, 2019 and for all prior years presented and have met all debt payment obligations. Refer to Note 6. "Indebtedness" within Item 1. *Financial Statements* for more details on these transactions.

During the three months ending September 30, 2019, we paid $3,300 to fulfill our liability under a class action lawsuit that was settled during our fiscal year ending March 31, 2020; see Note 10. “Commitments and Contingencies” within Item 1. *Financial Statements.*

Given our cash flow projections and cash on hand, our liquidity is strong and is expected to meet our ongoing cash and debt service requirements for our general business needs.

We routinely evaluate opportunities for strategic acquisitions. Although we currently have significant cash and cash equivalents on hand, future material acquisitions may require that we obtain additional capital, assume additional third party debt or incur other long-term obligations. We believe that we have the option to raise more equity or issue more debt in the future in order to finance our investment activities and acquisitions, should our capital requirements exceed our cash and cash equivalents. In June 2018, the SEC declared effective a shelf registration statement which allows us to sell, in one or more public offerings, common stock, warrants, or any combination of such securities for proceeds in an aggregate amount of up to $300,000. The terms of any offering, including the type of securities involved, would be established at the time of sale.

### Dividends

We have paid regular quarterly dividends since 2003. We declared and paid dividends of $0.16 per share for the three months ended September 30, 2019 as well as each quarter for the year ending March 31, 2019.

In October 2019, we announced that our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on December 16, 2019, to shareholders of record at the close of business on November 29, 2019.

### Cash Flows

Our cash flows from operating, investing, and financing activities were as follows (in thousands):

|  | Six Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $7,138 | $10,200 |
| Net cash (used in) provided by investing activities | (3,098) | 1,373 |
| Net cash provided by (used in) financing activities | 231,251 | (11,300) |

Cash flows from operations were lower in the six months ended September 30, 2019 due primarily to higher payments made for incentive compensation and federal income taxes. Cash used in investing decreased as a result of the acquisition of IBP in the current year and the sale of the Old Bozeman facility in the prior year. Cash provided by financing increased due to proceeds raised through our convertible debt offering and equity offering, which were both completed in August 2019, partially offset by increased payments of debt.

### Contractual Obligations and Other Commercial Commitments

We are party to many contractual obligations that involve commitments to make payments to third parties in the ordinary course of business. For a description of our contractual obligations and other commercial commitments as of March 31, 2019, see our Form 10-K for the fiscal year ended March 31, 2019, filed with the Securities and Exchange Commission on June 3, 2019. During the current quarter, there were no material changes with respect to the nature of our contractual obligations and other commercial commitments outside the ordinary course of business. At September 30, 2019, we had contractual obligations for open purchase orders of approximately $4,160 for routine purchases of supplies and inventory, which are payable in less than one year.

### Off-Balance Sheet Arrangements

As of September 30, 2019, we had no off-balance sheet arrangements or obligations.

### Critical Accounting Estimates

Critical accounting estimates are those that we believe are both significant and require us to make difficult, subjective, or complex judgments, often because we need to estimate the effect of inherently uncertain matters. These estimates are based on historical experience and various other factors that we believe to be appropriate under the circumstance. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2019 in the Critical Accounting Policies and Estimates section of “Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.”

## Market risk

As filed, 785 characters.

We have no derivative instruments and minimal exposure to commodity market risks. A portion of our operations consist of activities outside of the U.S. and we have currency risk on the transactions in other currencies and translation adjustments resulting from the conversion of our international financial results into the U.S. dollar. However, a substantial majority of our operations and investment activities are transacted in U.S. dollars and therefore our foreign currency risk is not material at this date. Beginning during the three months ended September 30, 2019, we held investments in money market funds. As a result, we are exposed to potential loss from market risks that may occur as a result of changes in interest rates, credit quality of the issuer, or other factors.

## Controls and procedures

As filed, 1,866 characters.

### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of September 30, 2019 based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at September 30, 2019.

### Changes in Internal Control Over Financial Reporting

On April 1, 2019, we adopted the new lease standard, as discussed in Note 1. "Description of Business and Summary of Significant Accounting Policies" and Note 5. "Leases" accompanying the Condensed Consolidated Financial Statements included within Item 1. “*Financial Statements”* of this report. As a result, we made additions and/or modifications to policies, procedures, systems and controls that have materially affected our internal control over financial reporting, including changes to accounting policies and procedures, operational processes and documentation practices.

## Risk factors

As filed, 5,106 characters.

We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition, or operating results are described in our Annual Report on Form 10-K for the year ended March 31, 2019, under the heading “Part I – Item 1A. Risk Factors.” Except as set forth below, there have been no material changes in our risk factors since our annual report on Form 10-K for the year ended March 31, 2019.

***Changes to policy regarding the treatment of kidney disease may adversely decrease demand for our Dialysis products and negatively impact our financial statements.***

During the six months ended September 30, 2019, an executive order was signed by the President of the United States that is intended to change the way that kidney care is delivered to patients and reimbursed through government-sponsored medical programs. The executive order has three key objectives: to increase the supply of kidneys available for transplants, to improve prevention and treatment of chronic kidney disease, and to encourage most dialysis patients to receive treatments through in-home care, rather than in a dialysis clinic. The extent of the impact of the executive order, as well as the timing of the impact on procedures and the market in general is currently unknown. Currently, our Dialyguard product line accounts for approximately one-third of the revenues and gross margin associated with our Instruments Division. The majority of the revenues in our Dialyguard business are associated with products that are used in dialysis clinics, while only a portion of our sales relate to in home care. If the executive order is successful at limiting the use of dialysis clinics, our financial statements, and the revenues and profits of the Instruments Division may be negatively impacted.

***Servicing our debt will require a significant amount of cash, and we may not have sufficient cash flow from our business or the ability to raise capital to repay the notes at maturity or repurchase the notes in the event of a fundamental change.***

We incurred significant indebtedness in the amount of $172,500 in the form of the Notes which mature on August 15, 2025 unless earlier converted.

We currently expect to settle future conversions solely in shares of our common stock, which has the effect of including the shares of common stock issuable upon conversion of the Notes in our diluted earnings per share to the extent such shares are not anti-dilutive. We will reevaluate this policy from time to time as conversion notices are received from holders of the Notes. Holders of the Notes also have the right to require us to repurchase all or a portion of their Notes upon the occurrence of a fundamental change (as defined in the applicable indenture governing the Notes) at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest. If the Notes have not previously been converted or repurchased, we will be required to repay the Notes in cash at maturity.

Our ability to make required cash payments in connection with conversions of the Notes, repurchase the Notes in the event of a fundamental change, or to repay or refinance the Notes at maturity will depend on market conditions and our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. We also may not use the cash proceeds we raised through the issuance of the Notes in an optimally productive and profitable manner.

In addition, our ability to repurchase or to pay cash upon conversion or at maturity of the Notes may be limited by law or regulatory authority. Our failure to repurchase Notes following a fundamental change or at maturity of the Notes as required by the applicable indenture would constitute a default under such indenture. A default under the applicable indenture or agreements governing our future indebtedness could have a material adverse effect on our business, results of operations, and financial condition. If the payment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or to pay cash upon conversion or at maturity of the Notes.

***Additional stock issuances could result in significant dilution to our stockholders.***

We may issue additional equity securities to raise capital, make acquisitions, or for a variety of other purposes. Additional issuances of our stock may be made pursuant to the exercise or conversion of new or existing convertible debt securities, warrants, stock options, or other equity incentive awards. Any such issuances will result in dilution to existing holders of our stock. We rely on equity-based compensation as an important tool in recruiting and retaining employees. The amount of dilution due to equity-based compensation of our employees and other additional issuances could be substantial.

Filed Nov 6, 2019.
Source: SEC EDGAR, the filing index for accession 0001437749-19-021657. Last ingested by Listed: Nov 13, 2026, 07:45 ET. No prices; not investment advice.
